Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
Yes === Objectives: Resistance-associated variants (RAVs) in Rv0678, a regulator of the MmpS5-MmpL5 efflux pump, have been shown to lead to increased MICs of bedaquiline (2- to 8- fold) and clofazimine (2- to 4-fold). The prevalence of these Rv0678 RAVs in clinical isolates and their impact on tre...
| Main Authors: | , , , , , , |
|---|---|
| Language: | en |
| Published: |
2019
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10454/17329 |